Parkinson's disease-like syndrome in rats induced by 2,9-dimethyl-β- carbolinium ion, a β-carboline occurring in the human brain

Behavioural Pharmacology

Volumn 17, Issue 5-6, 2006, Pages 463-473

  Lorenc Koci, Elzbieta ^a   Rommelspacher, Hans ^b   Schulze, Gert ^b   Wernicke, Catrin ^b   Kuter, Katarzyna ^a   Śmiałowska, Maria ^a   Wierońska, Joana ^a   Ziȩba, Barbara ^a   Ossowska, Krystyna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

carboline; 1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Electromyogram; Mechanomyogram; Muscle tone; Neurotoxicity; Parkinson's disease; Rat; Rigor; Substantia nigra

Indexed keywords

2,9 DIMETHYL BETA CARBOLINIUM ION; BETA CARBOLINE; DOPAMINE; ION; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; BRAIN SIZE; CELL COUNT; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; ELECTROMYOGRAPHY; IMMUNOCOMPETENT CELL; MALE; MUSCLE CONTRACTION; MUSCLE TONE; NONHUMAN; PARKINSON DISEASE; RAT; STEREOMETRY; SUBSTANTIA NIGRA;

ANIMALS; CARBOLINES; CELL COUNT; CORPUS STRIATUM; DOMINANCE, CEREBRAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROMYOGRAPHY; HUMANS; MALE; MUSCLE TONUS; NEURAL PATHWAYS; NEURONS; NEUROTOXINS; PARKINSONIAN DISORDERS; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 33748313157     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200609000-00012     Document Type: Article

References (57)

1. Abou-Sleiman PM, Muqit MMK, Wood NW (2006). Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 7:207-219.
2. Benazzouz A, Gross C, Dupont J, Bioulac B (1992). MPTP induced hemiparkinsonism in monkeys - behavioral, mechanographic, electromyographic and immunohistochemical studies. Exp Brain Res 90:116-120.
3. Bonnet R, Pavlovic S, Lehmann J, Rommelspacher H (2004). The strong inhibition of triosephosphate isomerase by the natural β-carbolines may explain their neurotoxic actions. Neuroscience 127:443-453.
4. Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211.
5. Chiueh CC, Markey SD, Burns RS, Johannessen JN, Jakobowitz DM, Kopin IJ (1984). Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. Psychopharmacol Bull 20:548-553.
6. Collins MA, Neafsey EJ (2001). β-Carboline analogues of MPP+ as environmental neurotoxins. In: Storch A, Collins MA, editors. Neurotoxic factors in Parkinson's disease and related disorders. New York: Kluwer-Plenum Publishers. pp. 115-130.
7. Collins MA, Neafsey EJ, Matsubara K, Cobuzzi RJ, Rollema H (1992). Indole-N-methylated β-carbolinium ions as potential brain-bioactivated toxins. Brain Res 505:154-160.
8. + in mesencephalic cultures. Abst Soc Neurosci 21:1259.
9. Davis G, Williams A, Markey S, Ebert M, Caine E, Reichert C, Kopin I (1979). Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatr Res 1:249-254.
10. Delwaide PJ (2001). Parkinsonian rigidity. Funct Neurol 16:147-156.
11. Ehringer H, Hornykiewicz O (1960). Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems [Distribution of noradrenaline and dopamine (3-hydroxytyramin) in the human brain and the changes by diseases of the extrapyramidal system]. Klin Wochenschrift 38:1236-1239.
12. Elsworth JD, Deutch AY, Redmond DE Jr, Tayler JR, Sladek JR Jr, Roth RH (1989). Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated primates: biochemical changes in striatal regions. Neuroscience 33:323-331.
13. Emborg-Knott ME, Domino EF (1998). MPTP-induced hemiparkinsonism in nonhuman primates 6-8 years after a single unilateral intracarotic dose. Exp Neurol 152:214-220.
14. Gearhart DA, Collins MA, Lee JM, Neafsey EJ (2000). Increased β-carboline 9N-methyltransferase activity in the frontal cortex in Parkinson's disease. Neurobiol Dis 7:210-211.
15. Gearhart DA, Neafsey EJ, Collins MA (2002). Phenylethanolamine-N- methyltransferase has β-carboline 2N-methyltransferase activity: hypothetical relevance to Parkinson's disease. Neurochem Int 40:611-620.
16. Gerlach M, Riederer P (1996). Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987-1041.
17. Gerlach M, Russ H, Winker J, Witzmann K, Traber J, Stasch JP, et al. (1993). Effects of nimodipine on the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced depletions in the biogenic amine levels in mice. Arzneimittelforsch/Drug Res 43:413-415.
18. Giovanni A, Sieber B-A, Heikkila RE, Sonsalla P (1994a). Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Part 1: Systemic administration. J Pharmacol Exp Ther 270:1000-1007.
19. Giovanni A, Sonsalla P, Heikkila RE (1994b). Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Part 2: Central administration of 1-methyl-4- phenylpyridinium. J Pharmacol Exp Ther 270:1008-1014.
20. Greiner B, Fähndrich C, Strauss S, Rommelspacher H (1982). Pharmacokinetics of tetrahydronorharmane (tetrahydro-β-carboline) in rats. Naunyn-Schmiedeberg's Arch Pharmacol 322:140-146.
21. Gundersen HJ, Jensen EB (1987). The efficiency of systematic sampling in stereology and its prediction. J Microsc 147:29-63.
22. Hamann J, Rommelspacher H, Storch A, Reichmann H, Gille G (2006). Neurotoxic mechanisms of 2,9-dimethyl-β-carbolinium ion in primary dopaminergic culture. J Neurochem [Epub ahead of print: 19 June 2006].
23. Ho BT, Gardner PM, Walker KE (1973). Inhibition of MAO by β-carbolinium halides. J Pharm Sci 62:36-39.
24. Honecker H, Rommelspacher H (1978). Tetrahydronorharman (tetrahydro-β-carboline) a physiologically occurring compound of indole metabolism. Naunyn Schmiedeberg's Arch Pharmacol 305:135-141.
25. Hornykiewicz O, Kish SJ (1986). Biochemical pathophysiology of Parkinson's disease. In: Yahr MD, Bergmann KJ, editors. Advanced Neurology. Vol. 45. New York: Raven Press. pp. 19-34.
26. Inoue H, Castagnoli K, Van der Schyf C, Mabic S, Igarashi K, Castagnoli N Jr (1999). Species-dependent differences in monoamine oxidase A and B-catalysed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridinyl derivatives. J Pharmacol Exp Ther 291:856-864.
27. Irwin I, Finnegan KT, Delanney LE, Di Monte D, Langston JW (1992). The relationships between aging, monoamine oxidases, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment. Brain Res 572:224-231.
28. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH (1985). Parkinson-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82:2173-2177.
29. Kalaria RN, Harik SI (1987). Blood-brain barrier monoamine oxidase: enzyme characterization in cerebral microvessels and other tissues from six mammalian species. J Neurochem 49:856-864.
30. Karbe H, Holthoff V, Huber M, Herholz K, Wienhard K, Wagner R, Heiss WD (1992). positron emission tomography in degenerative disorders of the dopaminergic system. J Neural Transm (P-D Sect) 4:121-130.
31. Kish SJ, Shannak K, Hornykiewicz O (1988). Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318:876-880.
32. Kuhn W, Müller Th, Grosse H, Dierks T, Rommelspacher H (1995). Plasma levels of the beta-carbolines harman and norharman in Parkinson's disease. Acta Neurol Scand 92:451-454.
33. Kuhn W, Müller Th, Grosse H, Rommelspacher H (1996). Elevated levels of harman and norharman in cerebrospinal fluid of Parkinsonian patients. J Neural Transm 103:1435-1440.
34. Langston JW, Ballard P, Tetrud JW, Irwin I (1983). Chronic Parkinsonism in humans due to a product of meperidine analog synthesis. Science 219:979-980.
35. Lee RG (1989). Pathophysiology of rigidity and akinesia in Parkinson's disease. Eur Neurol 29 (Suppl 1):13-18.
36. Lorenc-Koci E, Ossowska K, Wardas J, Wolfarth S (1995). Does reserpine induce Parkinsonian rigidity? J Neural Transm [P-D Sect] 9:211-223.
37. Lorenc-Koci E, Wolfarth S, Ossowska K (1996). Haloperidol-increased muscle tone in rats as a model of Parkinsonian rigidity. Exp Brain Res 109:268-276.
38. Matsubara K, Neafsey EJ, Collins M (1992). Novel S-adenosylmethionine- dependent indole-N-methylation of β-carbolines in brain particulate fractions. J Neurochem 59:511-518.
39. Matsubara K, Collins MA, Akane A, Ikebuchi J, Neafsey EJ, Kagawa M, Shiono H (1993). Potential bioactivated neurotoxicants, N-methylated β-carbolinium ions, are present in human brain. Brain Res 610:90-96.
40. + analogs, in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Neurology 45:2240-2245.
41. Matsubara K, Gonda T, Sawada H, Uezono T, Kobayashi Y, Kawamura T, et al. (1998). Endogenously occurring β-carboline induces Parkinsonism in nonprimate animals: a possible causative protoxin in idiopathic Parkinson's disease. J Neurochem 70:727-735.
42. Matsubara K, Aoyama K, Suno M, Awaya T (2002). N-methylation underlying Parkinson's disease. Neurotox Teratol 24:593-598.
43. McGeer PL, Itagaki S, Akijama H, McGeer EG (1989). Comparison of neuronal loss in Parkinson's disease and aging. In: Calne DB, editor. Parkinsonism and aging. New York: Raven Press. pp. 25-34.
44. Neafsey EJ, Albores R, Gearhart D, Kindel G, Raikoff K, Tamayo F, Collins MA (1995). Methyl-β-carbolinium analogs of MPP+ cause nigrostriatal toxicity after substantia nigra injections in rats. Brain Res 675:279-288.
45. Ossowska K, Lorenc-Koci E, Schulze G, Konieczny J, Wolfarth S, Bojarski M, Coper H (1996). The role of reflex activity in the regulation of muscle tone in rats. Exp Physiol 81:211-223.
46. Ossowska K, Wardas J, Smialowska M, Kuter K, Lenda T, Wieronska JM, et al. (2005). A slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats: an animal model of preclinical stages of Parkinson's disease? Eur J Neurosci 22:1294-1304.
47. +). Neuroscience 139:1525-1537.
48. Paxinos C, Watson C (1986). The rat brain in stereotaxic coordinates. London: Academic Press.
49. Riachi NJ, Harik SI, Kalaria RN, Sayre LM (1988). On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity, II. Susceptibility among mammalian species correlates with the toxin's metabolic patterns in brain microvessels and liver. J Pharmcol Exp Ther 244:443-448.
50. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y (1983). Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275:321-328.
51. Smith AD, Zigmond MJ (2003). Can the brain be protected through exercise? Lessons from an animal model of Parkinsonism. Exp Neurol 184:31-39.
52. Sterio DC (1984). The unbiased estimation of number and sizes of arbitrary particles using the dissector. J Microsc 134:127-136.
53. Sundstrom E, Samuelsson EB (1997). Comparison of key steps in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in rodents. Pharmacol Toxicol 81:226-231.
54. Tedroff J, Aquilonius SM, Hartvig P, Lundquist H, Gee AG, Uhlin J, Langstrom B (1988). Monoamine re-uptake sites in the human brain evaluated in vivo by means of 11C-nomifensine and positron emission tomography: the effects of age and Parkinson's disease. Acta Neurol Scand 77:192-201.
55. Tipton KF, Singer TP (1993). Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61:1191-2006.
56. Wolf OT, Dyakin V, Patel A, Vadasz C, De Leon MJ, McEwen BS, Bulloch K (2002). Volumetric structural magnetic resonance imaging (MRI) of the rat hippocampus following kainic acid (KA) treatment. Brain Res 934:87-96.
57. Wolfarth S, Konieczny J, Śmiałowska K, Schulze G, Ossowska K (1996). Influence of 6-hydroxydopamine lesion of the dopaminergic nigrostriatal pathway on the muscle tone and electromyographic activity measured during passive movements. Neuroscience 74:985-996.